PLX3397

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent Glioblastoma

Conditions

Recurrent Glioblastoma

Trial Timeline

Dec 3, 2011 → Nov 5, 2013

NCT ID

NCT01349036

About PLX3397

PLX3397 is a phase 2 stage product being developed by Daiichi Sankyo for Recurrent Glioblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01349036. Target conditions include Recurrent Glioblastoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02975700	Pre-clinical	Completed	Jan 31, 2017	Oct 11, 2024	Melanoma
NCT01499043	Phase 2	Terminated	May 25, 2012	Mar 11, 2013	Prostate Cancer
NCT01349036	Phase 2	Terminated	Dec 3, 2011	Nov 5, 2013	Recurrent Glioblastoma
NCT01217229	Phase 2	Completed	Mar 3, 2011	Apr 26, 2012	Hodgkin Lymphoma
NCT01004861	Phase 1	Completed	Oct 1, 2009	Oct 25, 2018	Solid Tumor

Competing Products

20 competing products in Recurrent Glioblastoma

See all competitors

Product	Company	Stage	Hype Score
KPL-914	Kiniksa Pharmaceuticals	Phase 2	47
KPL-387	Kiniksa Pharmaceuticals	Phase 2	47
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	72
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	33
Zopapogene imadenovec (Zopa)	Precigen	Approved	80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	36
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	52
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	41
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	33
erlotinib + etoposide	Astellas Pharma	Phase 2	52
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	52
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
Eribulin Mesylate	Eisai	Pre-clinical	23
Lenvatinib + Everolimus	Eisai	Phase 1/2	41
E7090	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52
Eribulin mesilate + Irinotecan hydrochloride	Eisai	Phase 1/2	41

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved